Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:42:00 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Q:BCRX - BIOCRYST PHARMACEUTICALS INC - https://www.biocryst.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BCRX - Q0.16.21·9.980.36.38+0.142.26,346.439,82814,1386.435  6.435  6.26111.31  6.0019:30:55Feb 0515 min RT 2¢

Recent Trades - Last 10 of 14138
Time ETExPriceChangeVolume
19:30:55Q6.35980.11986
17:11:59Q6.48670.2467250
17:09:40Q6.500.265
16:44:25Q6.490.252
16:40:09Q6.490.2512
16:10:04Q6.380.141
16:10:04Q6.380.141
16:04:57Q6.380.143,500,000
16:04:50Q6.380.141
16:04:47Q6.380.141

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-05 07:01U:BCRXNews ReleaseBioCryst to Report Fourth Quarter 2025 Financial Results on February 26
2026-02-05 07:00U:BCRXNews ReleaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-01-23 09:00U:BCRXNews ReleaseBioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
2026-01-12 07:00U:BCRXNews ReleaseBioCryst Announces Preliminary Full Year 2025 ORLADEYO(TM) (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range
2026-01-06 07:01U:BCRXNews ReleaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-01-06 07:00U:BCRXNews ReleaseBioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference
2025-12-12 07:00U:BCRXNews ReleaseBioCryst Announces FDA Approval of ORLADEYO(TM) (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years
2025-12-04 07:00U:BCRXNews ReleaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-12-03 07:00U:BCRXNews ReleaseBioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition
2025-11-12 08:00U:BCRXNews ReleaseAstria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
2025-11-06 08:00U:BCRXNews ReleaseBioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO(TM) (berotralstat)
2025-11-05 07:01U:BCRXNews ReleaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-05 07:00U:BCRXNews ReleaseBioCryst to Present at Upcoming Investor Conference
2025-11-03 07:00U:BCRXNews ReleaseBioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update
2025-10-23 07:00U:BCRXNews ReleaseBioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
2025-10-20 07:00U:BCRXNews ReleaseBioCryst to Report Third Quarter 2025 Financial Results on November 3
2025-10-14 07:01U:BCRXNews ReleaseBioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
2025-10-03 07:00U:BCRXNews ReleaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-10-01 07:00U:BCRXNews ReleaseBioCryst Completes Sale of European ORLADEYO(TM) (berotralstat) Business